Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Immunitybio Inc's Business Segments
Immunitybio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 51
Regions Reported
1
Revenue Share by Reportable Segment - Q2 FY2026
- Reportable100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 51 | 100% |
Revenue Share by Region - Q2 FY2026
- Europe1%
Revenue by Geographic Region - Q2 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 1 | 1% |
Revenue by Product & Service Category - Q2 FY2026
- Product98.9%
- Product and Service, Other1.1%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 51 | 98.9% |
| Product and Service, Other | $ 1 | 1.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Immunitybio Inc
Immunitybio Inc. is a biotechnology company that specializes in developing and commercializing immunotherapy treatments for various diseases, including cancer, infectious diseases, and autoimmune disorders. The company focuses on designing and engineering novel immunotherapies to enhance the immune response and target specific disease biomarkers.
One of Immunitybio's primary goals is to create a new generation of vaccines and immunotherapies that provide effective, long-lasting protection against diseases. They combine expertise in immunology, stem cell biology, bioengineering, and genomics to develop innovative treatments that can be tailored to individual patients.
The company's flagship technology platform is called N-803, a cytokine-based molecule designed to boost the immune system's response to cancer cells. N-803 is being investigated in various clinical trials in combination with other immunotherapies and chemotherapy agents for the treatment of solid tumors, lymphomas, and viral infections.
Immunitybio also focuses on developing personalized, off-the-shelf natural killer (NK) cell-based immunotherapies. NK cells are a type of immune cell that can recognize and kill abnormal cells, including cancer cells. The company has developed a proprietary technique to harvest and expand NK cells from healthy donors, enabling the creation of a scalable cell therapy product that can be readily available to patients.
Furthermore, Immunitybio is actively involved in developing targeted antibody-drug conjugates (ADCs) and tumor-targeting bacteria for cancer treatment. ADCs are molecules that selectively deliver cytotoxic drugs to cancer cells, while tumor-targeting bacteria are engineered to colonize and destroy cancerous tissues.
In addition to their cancer immunotherapy programs, Immunitybio has also been involved in developing candidate vaccines against COVID-19 and other infectious diseases. They utilize their expertise in immunoengineering to create vaccines that induce robust and durable immune responses against specific pathogens.
Overall, Immunitybio Inc. is focused on leveraging the power of the immune system to develop groundbreaking treatments for a wide range of diseases. Their extensive research and development efforts in immunotherapy, coupled with their innovative technology platforms, position them at the forefront of the biotechnology industry in the quest to revolutionize disease treatment and prevention.
One of Immunitybio's primary goals is to create a new generation of vaccines and immunotherapies that provide effective, long-lasting protection against diseases. They combine expertise in immunology, stem cell biology, bioengineering, and genomics to develop innovative treatments that can be tailored to individual patients.
The company's flagship technology platform is called N-803, a cytokine-based molecule designed to boost the immune system's response to cancer cells. N-803 is being investigated in various clinical trials in combination with other immunotherapies and chemotherapy agents for the treatment of solid tumors, lymphomas, and viral infections.
Immunitybio also focuses on developing personalized, off-the-shelf natural killer (NK) cell-based immunotherapies. NK cells are a type of immune cell that can recognize and kill abnormal cells, including cancer cells. The company has developed a proprietary technique to harvest and expand NK cells from healthy donors, enabling the creation of a scalable cell therapy product that can be readily available to patients.
Furthermore, Immunitybio is actively involved in developing targeted antibody-drug conjugates (ADCs) and tumor-targeting bacteria for cancer treatment. ADCs are molecules that selectively deliver cytotoxic drugs to cancer cells, while tumor-targeting bacteria are engineered to colonize and destroy cancerous tissues.
In addition to their cancer immunotherapy programs, Immunitybio has also been involved in developing candidate vaccines against COVID-19 and other infectious diseases. They utilize their expertise in immunoengineering to create vaccines that induce robust and durable immune responses against specific pathogens.
Overall, Immunitybio Inc. is focused on leveraging the power of the immune system to develop groundbreaking treatments for a wide range of diseases. Their extensive research and development efforts in immunotherapy, coupled with their innovative technology platforms, position them at the forefront of the biotechnology industry in the quest to revolutionize disease treatment and prevention.
ImmunityBio Inc. is a prominent biopharmaceutical company dedicated to the development and commercialization of innovative therapies that enhance the human immune systems ability to combat various diseases, most notably cancer and infectious diseases. The company’s commitment to advancing immunotherapy is evidenced through its extensive portfolio of segments, products, and services, each designed to contribute to improved patient outcomes and renew the field of immunotherapy. Below is a thorough exploration of ImmunityBios offerings:
1. Immunotherapies
ImmunityBios immunotherapy portfolio comprises a range of therapeutic options harnessing the body’s immune system to target and eliminate cancer cells:
- Multi-functional Biological Molecules: Central to the company’s approach are proprietary agents known as N Kris®, designed to direct various immune cells towards cancerous cells while also fostering immune memory, providing long-term protection against cancer recurrence.
- Flagship Products:
- Anktiva® (N-803): This novel interleukin-15 (IL-15) superagonist is engineered to significantly amplify the activity of natural killer (NK) cells and CD8+ T-cells against tumors. It enhances the proliferation and activation of these immune cells, increasing their ability to detect and destroy cancer cells.
- Combination Therapies: ImmunityBio also investigates combining its immunotherapies with other treatment modalities like chemotherapy and radiation to synergistically boost overall therapeutic efficacy against various malignancies.
Infectious Disease Vaccines
ImmunityBio is pioneering the development of vaccines aimed at preventing and treating infectious diseases through innovative platform technologies:
- Vaccine Platforms: Utilizing the hAd5 (human adenovirus type five) system, ImmunityBio designs vaccines that deliver multiple antigens, inducing robust immune responses and offering broad protection against various pathogens.
- Vaccine Candidates:
- COVID-19: ImmunityBio has developed vaccine candidates aimed at eliciting strong immune responses against the virus responsible for COVID-19.
- Zika and Chikungunya Viruses: The company is also developing vaccines targeting these infectious agents.
- Universal Influenza Vaccine: Aiming to improve annual vaccinations, ImmunityBio is working on a universal flu vaccine that targets numerous strains, enhancing protective efficacy and reducing the frequency of required immunizations.
Cell Therapy
ImmunityBios commitment to advancing cell therapy leverages the power of engineered immune cells to treat malignancies:
- Innovative Cellular Therapies:
- Allogeneic Natural Killer (NK) Cells: These therapies utilize NK cells from donors to reduce cancer cell burdens effectively.
- T-cell Receptor (TCR) Engineered T Cells and CAR T Cells: The company is developing TCR-engineered and CAR T cells that enhance the ability of T cells to recognize and attack tumors.
- CAR-NKT Cells: These are chimeric antigen receptor-natural killer T (CAR-NKT) cells that have shown promise in preclinical research, particularly for solid tumors as well as hematological cancers, exemplifying the company’s innovation in combining different immune cell types for optimal therapeutic outcomes.
Clinical Trials and Collaborations
To ensure a rigorous evaluation of their therapies, ImmunityBio engages in extensive clinical research:
- Clinical Trials: The company conducts a wide array of clinical trials to assess the safety and effectiveness of its immuno-oncology products, often in partnership with leading hospitals, research institutions, and academic centers.
- Collaborations: ImmunityBio collaborates with various stakeholders, including pharmaceutical companies and government entities, to facilitate the rapid development and commercialization of novel immunotherapies. These partnerships enhance research capabilities and speed up timelines for bringing therapies to market.
Diagnostic Services
In supporting personalized medicine, ImmunityBio offers diagnostic services aimed at better treatment stratification:
- Biomarker Assessment: The companys diagnostic offerings include tests that assess the expression of specific biomarkers in tumors. These tests help identify patients with high immunogenicity, thereby facilitating tailored treatment approaches based on patient profiles.
- Impact on Treatment Decisions: By identifying patients likely to respond to immunotherapies, ImmunityBio helps clinicians optimize treatment plans, improving chances for better outcomes and reducing potential side effects.
Conclusion
ImmunityBio Inc. stands at the forefront of biopharmaceutical innovation, offering a comprehensive suite of products and services designed to advance the field of immunotherapy. Through its diverse offerings in immunotherapies, vaccines for infectious diseases, cutting-edge cell therapies, engaged clinical research, and dedicated diagnostic services, the company strives to transform the landscape of disease treatment, particularly in oncology and infectious diseases. These advancements not only highlight ImmunityBios commitment to improving patient outcomes but significantly contribute to the evolution of healthcare practices in immunotherapy.
1. Immunotherapies
ImmunityBios immunotherapy portfolio comprises a range of therapeutic options harnessing the body’s immune system to target and eliminate cancer cells:
- Multi-functional Biological Molecules: Central to the company’s approach are proprietary agents known as N Kris®, designed to direct various immune cells towards cancerous cells while also fostering immune memory, providing long-term protection against cancer recurrence.
- Flagship Products:
- Anktiva® (N-803): This novel interleukin-15 (IL-15) superagonist is engineered to significantly amplify the activity of natural killer (NK) cells and CD8+ T-cells against tumors. It enhances the proliferation and activation of these immune cells, increasing their ability to detect and destroy cancer cells.
- Combination Therapies: ImmunityBio also investigates combining its immunotherapies with other treatment modalities like chemotherapy and radiation to synergistically boost overall therapeutic efficacy against various malignancies.
Infectious Disease Vaccines
ImmunityBio is pioneering the development of vaccines aimed at preventing and treating infectious diseases through innovative platform technologies:
- Vaccine Platforms: Utilizing the hAd5 (human adenovirus type five) system, ImmunityBio designs vaccines that deliver multiple antigens, inducing robust immune responses and offering broad protection against various pathogens.
- Vaccine Candidates:
- COVID-19: ImmunityBio has developed vaccine candidates aimed at eliciting strong immune responses against the virus responsible for COVID-19.
- Zika and Chikungunya Viruses: The company is also developing vaccines targeting these infectious agents.
- Universal Influenza Vaccine: Aiming to improve annual vaccinations, ImmunityBio is working on a universal flu vaccine that targets numerous strains, enhancing protective efficacy and reducing the frequency of required immunizations.
Cell Therapy
ImmunityBios commitment to advancing cell therapy leverages the power of engineered immune cells to treat malignancies:
- Innovative Cellular Therapies:
- Allogeneic Natural Killer (NK) Cells: These therapies utilize NK cells from donors to reduce cancer cell burdens effectively.
- T-cell Receptor (TCR) Engineered T Cells and CAR T Cells: The company is developing TCR-engineered and CAR T cells that enhance the ability of T cells to recognize and attack tumors.
- CAR-NKT Cells: These are chimeric antigen receptor-natural killer T (CAR-NKT) cells that have shown promise in preclinical research, particularly for solid tumors as well as hematological cancers, exemplifying the company’s innovation in combining different immune cell types for optimal therapeutic outcomes.
Clinical Trials and Collaborations
To ensure a rigorous evaluation of their therapies, ImmunityBio engages in extensive clinical research:
- Clinical Trials: The company conducts a wide array of clinical trials to assess the safety and effectiveness of its immuno-oncology products, often in partnership with leading hospitals, research institutions, and academic centers.
- Collaborations: ImmunityBio collaborates with various stakeholders, including pharmaceutical companies and government entities, to facilitate the rapid development and commercialization of novel immunotherapies. These partnerships enhance research capabilities and speed up timelines for bringing therapies to market.
Diagnostic Services
In supporting personalized medicine, ImmunityBio offers diagnostic services aimed at better treatment stratification:
- Biomarker Assessment: The companys diagnostic offerings include tests that assess the expression of specific biomarkers in tumors. These tests help identify patients with high immunogenicity, thereby facilitating tailored treatment approaches based on patient profiles.
- Impact on Treatment Decisions: By identifying patients likely to respond to immunotherapies, ImmunityBio helps clinicians optimize treatment plans, improving chances for better outcomes and reducing potential side effects.
Conclusion
ImmunityBio Inc. stands at the forefront of biopharmaceutical innovation, offering a comprehensive suite of products and services designed to advance the field of immunotherapy. Through its diverse offerings in immunotherapies, vaccines for infectious diseases, cutting-edge cell therapies, engaged clinical research, and dedicated diagnostic services, the company strives to transform the landscape of disease treatment, particularly in oncology and infectious diseases. These advancements not only highlight ImmunityBios commitment to improving patient outcomes but significantly contribute to the evolution of healthcare practices in immunotherapy.